S&P 500   4,582.40 (+0.67%)
DOW   35,632.86 (+0.40%)
QQQ   383.01 (+0.79%)
AAPL   152.31 (+2.32%)
MSFT   322.84 (-0.10%)
FB   314.99 (+0.89%)
GOOGL   2,922.13 (-0.08%)
TSLA   1,070.79 (+3.17%)
AMZN   3,469.43 (+2.27%)
NVDA   246.90 (+0.98%)
BABA   169.76 (+0.31%)
NIO   40.32 (+2.57%)
CGC   12.86 (+0.63%)
GE   104.11 (+0.25%)
AMD   120.90 (-1.13%)
MU   69.32 (+1.58%)
T   25.59 (+2.11%)
F   16.90 (+8.96%)
ACB   6.86 (+0.29%)
DIS   170.14 (+0.35%)
PFE   43.16 (+0.44%)
BA   206.72 (+0.05%)
AMC   34.98 (+0.63%)
S&P 500   4,582.40 (+0.67%)
DOW   35,632.86 (+0.40%)
QQQ   383.01 (+0.79%)
AAPL   152.31 (+2.32%)
MSFT   322.84 (-0.10%)
FB   314.99 (+0.89%)
GOOGL   2,922.13 (-0.08%)
TSLA   1,070.79 (+3.17%)
AMZN   3,469.43 (+2.27%)
NVDA   246.90 (+0.98%)
BABA   169.76 (+0.31%)
NIO   40.32 (+2.57%)
CGC   12.86 (+0.63%)
GE   104.11 (+0.25%)
AMD   120.90 (-1.13%)
MU   69.32 (+1.58%)
T   25.59 (+2.11%)
F   16.90 (+8.96%)
ACB   6.86 (+0.29%)
DIS   170.14 (+0.35%)
PFE   43.16 (+0.44%)
BA   206.72 (+0.05%)
AMC   34.98 (+0.63%)
S&P 500   4,582.40 (+0.67%)
DOW   35,632.86 (+0.40%)
QQQ   383.01 (+0.79%)
AAPL   152.31 (+2.32%)
MSFT   322.84 (-0.10%)
FB   314.99 (+0.89%)
GOOGL   2,922.13 (-0.08%)
TSLA   1,070.79 (+3.17%)
AMZN   3,469.43 (+2.27%)
NVDA   246.90 (+0.98%)
BABA   169.76 (+0.31%)
NIO   40.32 (+2.57%)
CGC   12.86 (+0.63%)
GE   104.11 (+0.25%)
AMD   120.90 (-1.13%)
MU   69.32 (+1.58%)
T   25.59 (+2.11%)
F   16.90 (+8.96%)
ACB   6.86 (+0.29%)
DIS   170.14 (+0.35%)
PFE   43.16 (+0.44%)
BA   206.72 (+0.05%)
AMC   34.98 (+0.63%)
S&P 500   4,582.40 (+0.67%)
DOW   35,632.86 (+0.40%)
QQQ   383.01 (+0.79%)
AAPL   152.31 (+2.32%)
MSFT   322.84 (-0.10%)
FB   314.99 (+0.89%)
GOOGL   2,922.13 (-0.08%)
TSLA   1,070.79 (+3.17%)
AMZN   3,469.43 (+2.27%)
NVDA   246.90 (+0.98%)
BABA   169.76 (+0.31%)
NIO   40.32 (+2.57%)
CGC   12.86 (+0.63%)
GE   104.11 (+0.25%)
AMD   120.90 (-1.13%)
MU   69.32 (+1.58%)
T   25.59 (+2.11%)
F   16.90 (+8.96%)
ACB   6.86 (+0.29%)
DIS   170.14 (+0.35%)
PFE   43.16 (+0.44%)
BA   206.72 (+0.05%)
AMC   34.98 (+0.63%)
NASDAQ:IMTX

Immatics News Headlines

$13.55
+0.10 (+0.74 %)
(As of 10/28/2021 11:35 AM ET)
Add
Compare
Today's Range
$13.49
$13.60
50-Day Range
$11.58
$15.46
52-Week Range
$9.58
$18.42
Volume
1,313 shs
Average Volume
327,508 shs
Market Capitalization
$852.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



Immatics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IMTX
News Sentiment

-0.11

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IMTX Articles
This Week

2

0

IMTX Articles
Average Week

Get Immatics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.

Immatics (NASDAQ:IMTX) News Headlines Today

SourceHeadline
MarketBeat logoImmatics (NASDAQ:IMTX) Shares Gap Down to $13.42
americanbankingnews.com - October 22 at 11:57 AM
MarketBeat logo Brokerages Expect Immatics (NASDAQ:IMTX) Will Post Quarterly Sales of $13.28 Million
americanbankingnews.com - October 20 at 5:22 AM
MarketBeat logoZacks: Analysts Expect Immatics (NASDAQ:IMTX) Will Announce Earnings of -$0.31 Per Share
americanbankingnews.com - October 18 at 5:20 AM
MarketBeat logoImmatics (NASDAQ:IMTX) Stock Price Down 3.6%
americanbankingnews.com - October 15 at 1:43 PM
MarketBeat logoStock Traders Purchase High Volume of Immatics Call Options (NASDAQ:IMTX)
americanbankingnews.com - October 13 at 5:52 PM
MarketBeat logoImmatics (NASDAQ:IMTX) Shares Down 2.9%
americanbankingnews.com - October 7 at 1:20 PM
nasdaq.com logoImmatics' (NASDAQ:IMTX) investors will be pleased with their 18% return over the last year - Nasdaq
nasdaq.com - August 20 at 5:23 PM
finance.yahoo.com logoInvestors in Immatics (NASDAQ:IMTX) have made a return of 18% over the past year
finance.yahoo.com - August 20 at 8:04 AM
globenewswire.com logoImmatics Announces Second Quarter 2021 Financial Results - GlobeNewswire
globenewswire.com - August 10 at 7:49 PM
benzinga.com logoImmatics: Q2 Earnings Insights - Benzinga
benzinga.com - August 10 at 2:49 PM
finance.yahoo.com logoImmatics Announces Second Quarter 2021 Financial Results and Provides Business Update - Yahoo Finance
finance.yahoo.com - August 10 at 2:49 PM
finance.yahoo.com logoImmatics Announces Second Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - August 10 at 2:48 PM
streetinsider.com logoForm 6-K Immatics NV For: Aug 10 - StreetInsider.com
streetinsider.com - August 10 at 9:48 AM
nasdaq.com logoImmatics N.V. Ordinary Shares (IMTX)
nasdaq.com - August 6 at 10:15 PM
streetinsider.com logoForm F-3 Immatics NV - StreetInsider.com
streetinsider.com - August 3 at 12:25 AM
streetinsider.com logoForm POS AM Immatics NV - StreetInsider.com
streetinsider.com - August 2 at 2:24 PM
finance.yahoo.com logoIs Immatics N.V. (IMTX) A Good Stock To Buy?
finance.yahoo.com - July 19 at 7:59 PM
seekingalpha.com logoBioCopy collaborates with Immatics to characterize TCR-peptide-HLA interactions in cancer
seekingalpha.com - July 7 at 7:13 AM
businesswire.com logoSelexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND
businesswire.com - June 29 at 1:37 PM
finance.yahoo.com logoImmatics Announces Changes to its Board of Directors
finance.yahoo.com - May 26 at 10:00 AM
nasdaq.com logoEarnings Update: Immatics N.V. (NASDAQ:IMTX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
nasdaq.com - May 22 at 7:20 PM
finance.yahoo.com logoImmatics N.V. (NASDAQ:IMTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
finance.yahoo.com - May 22 at 2:19 PM
finance.yahoo.com logoImmatics Announces First Quarter 2021 Financial Results and Business Update
finance.yahoo.com - May 18 at 10:15 AM
seekingalpha.com logoImmatics reports Q1 results
seekingalpha.com - May 18 at 7:30 AM
markets.businessinsider.com logohttps://immatics.com/ : Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
markets.businessinsider.com - May 15 at 12:32 AM
finance.yahoo.com logoImmatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
finance.yahoo.com - May 11 at 9:12 AM
nasdaq.com logoIf You Had Bought Heat Biologics' (NASDAQ:HTBX) Shares Five Years Ago You Would Be Down 88% - Nasdaq
nasdaq.com - April 22 at 1:29 PM
nasdaq.com logoAre Institutions Heavily Invested In Immatics N.V.'s (NASDAQ:IMTX) Shares? - Nasdaq
nasdaq.com - April 21 at 7:49 PM
finance.yahoo.com logoWhat Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)? - Yahoo Finance
finance.yahoo.com - April 3 at 11:32 AM
finance.yahoo.com logoWhat Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)?
finance.yahoo.com - April 3 at 11:32 AM
streetinsider.com logoForm 20-F Immatics NV For: Dec 31 - StreetInsider.com
streetinsider.com - March 30 at 11:13 PM
markets.businessinsider.com logoImmatics Announces Full Year 2020 Financial Results and Corporate Update
markets.businessinsider.com - March 30 at 1:12 PM
finance.yahoo.com logoImmatics Announces Full Year 2020 Financial Results and Corporate Update - Yahoo Finance
finance.yahoo.com - March 30 at 8:12 AM
finance.yahoo.com logoImmatics Announces Full Year 2020 Financial Results and Corporate Update
finance.yahoo.com - March 30 at 8:12 AM
fool.com logoWhy Immatics Stock Is Soaring Today
fool.com - March 17 at 4:34 PM
markets.businessinsider.com logoImmatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients
markets.businessinsider.com - March 17 at 2:40 PM
finanznachrichten.de logohttps://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs
finanznachrichten.de - March 17 at 9:40 AM
finance.yahoo.com logoImmatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
finance.yahoo.com - March 17 at 9:40 AM
seekingalpha.com logoImmatics: Bursting With Big Pharma Partnerships
seekingalpha.com - March 15 at 11:22 PM
finance.yahoo.com logoIs IMTX A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 18 at 6:58 PM
finance.yahoo.com logoImmatics Announces Third Quarter 2020 Financial Results and Business Update
finance.yahoo.com - December 2 at 7:24 AM
finance.yahoo.com logoImmatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
finance.yahoo.com - November 10 at 7:31 AM
markets.businessinsider.com logoImmatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
markets.businessinsider.com - October 29 at 7:44 AM
finance.yahoo.com logoImmatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
finance.yahoo.com - October 29 at 7:44 AM
finance.yahoo.com logoImmatics Appoints Biotech Executive Eliot Forster to Board of Directors
finance.yahoo.com - September 15 at 7:31 AM
finance.yahoo.com logoImmatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment
finance.yahoo.com - September 10 at 8:32 AM
finance.yahoo.com logoImmatics Announces Second Quarter 2020 Financial Results and Business Update
finance.yahoo.com - September 3 at 8:57 AM
finance.yahoo.com logoImmatics Announces Board of Directors Additions Following Public Listing on NASDAQ
finance.yahoo.com - September 1 at 4:54 PM
finance.yahoo.com logoImmatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
finance.yahoo.com - September 1 at 4:54 PM
finance.yahoo.com logoImmatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
finance.yahoo.com - September 1 at 4:54 PM
Get Immatics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.